Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (November 2025)
38 slides from Immunome's investor presentation, November 2025
Slide 1: Immunome Corporate Presentation
Immunome Corporate Presentation November 2025
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclosures For purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, any oral presentation of the slides by members of management of Immunome, Inc. (“Immunome”) or any person on its behalf, any question-and-
Slide 3: Establishing a Premier Targeted Oncology Company
Establishing a Premier Targeted Oncology Company Upcoming Catalysts and a Foundation for Success Long-Term Corporate Vision • Varegacestat, an oral, once-daily gamma secretase inhibitor • Develop differentiated ADCs with a focus on first-in-class for the treatment of desmoid tumors, with Phase 3 top
Slide 4: Management Team with a Demonstrated Track Record of Success
Management Team with a Demonstrated Track Record of Success Clay Siegall, Ph.D. • Chief Executive Officer and Founder, Seagen (1998-2022) PRESIDENT & • Grew company to $2B+ revenue (2022) leading to $43B acquisition CHIEF EXECUTIVE OFFICER • Led development of 4 FDA-approved therapeutics • Raised ov
Slide 5: Pipeline Overview
Pipeline Overview Candidate Mechanism of Action Discovery Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone Varegacestat Phase 3 Topline Gamma Secretase Inhibitor (Formerly AL102) 2H25 Initial Lymphoma Data IM-1021 ROR1 ADC 2026 First Patient In IM-3050 FAP RLT Early 2026 IND Submission
Slide 6: Varegacestat
Varegacestat Phase 3 Oral, Once-Daily Gamma Secretase Inhibitor 6
Slide 7: Varegacestat May Address Substantial Unmet Patient Need in Desmoid Tumors
Varegacestat May Address Substantial Unmet Patient Need in Desmoid Tumors Desmoid Tumors Are Debilitating, Painful, and Varegacestat is a Potent Gamma Secretase Aggressive Inhibitor (GSI) • GSIs block the NOTCH pathway, which is believed to ~5,500-7,500 contribute to the growth of desmoid tumors Act
Slide 8: Varegacestat Data With Daily Dosing Shows Increased Response Compared to Nirogacestat
Varegacestat Data With Daily Dosing Shows Increased Response Compared to Nirogacestat Across All Measures • Varegacestat is being evaluated as an oral, ORR by RECIST once-daily GSI for the treatment of desmoid Evaluable tumors Varegacestat 1.2mg QD1 75% ITT Median ToT 16.6 months • Phase 2 RINGSIDE
Slide 9: Selected Phase 3 Dose of 1.2 mg Daily Shows Rapid Reduction in Tumor Burden
Selected Phase 3 Dose of 1.2 mg Daily Shows Rapid Reduction in Tumor Burden by Multiple Measures Phase 2 RINGSIDE Part A Data (Evaluable Patients) Source: Kasper B et al., ESMO Congress 2024_1766P (Cutoff Date – April 10, 2024) One patient previously reported as PR at ESMO subsequently progressed pr
Slide 10: Safety in Phase 2 Portion of RINGSIDE is consistent with GSI class
Safety in Phase 2 Portion of RINGSIDE is consistent with GSI class Study Population, n(%) Varegacestat, 1.2mg QD, (n=14) Nirogacestat 150mg BID (n=69) Any Grade Grade ≥3 Any Grade Grade ≥3 Diarrhoea 13 (92.8) 2 (14.3) 58 (84) 11 (16) Nausea 8 (57.1) – 37 (54) 1 (1) Fatigue 7 (50) – 35 (51) 2 (3) Alo
Slide 11: RINGSIDE Phase 3: Evaluating Safety and Efficacy in Progressing Desmoid Tumors
RINGSIDE Phase 3: Evaluating Safety and Efficacy in Progressing Desmoid Tumors Phase 3 (N=156) Phase 3 Randomized Double-Blind Placebo Controlled Key Inclusion Criteria Endpoints • Relapsed/refractory or treatment- • Primary: PFS naïve, with PD (per RECIST) • Secondary: ORR & DOR by BICR, in last 12
Slide 12: IM-1021 ROR1 ADC
IM-1021 ROR1 ADC 12
Slide 13: ROR1: Attractive ADC Target in Both Liquid and Solid Tumors
ROR1: Attractive ADC Target in Both Liquid and Solid Tumors ROR1 MK-2140 Monotherapy Demonstrates • Receptor with oncofetal expression pattern, Potential of ROR1 in B-Cell Lymphoma2 including little or no normal tissue expression1 45% • Expression on solid and liquid tumors 40% 35% PR CR Zilovertama
Slide 14: IM-1021: Potential Best-in-Class ROR1 ADC
IM-1021: Potential Best-in-Class ROR1 ADC Designed for Activity in Liquid and Solid Tumors IM-1021 Design ROR1 Expression by RNA2 • Antibody selected for ADC-specific properties • Proprietary HC74 payload may enable efficacy in lymphoma and solid tumors • Supports DAR 8 format • Enhanced bystander e
Slide 15: IM-1021's Payload, HC74, May Allow for Higher Clinical Dose
IM-1021’s Payload, HC74, May Allow for Higher Clinical Dose, Increasing Therapeutic Index ADCs Containing TOP1 Inhibitors Achieve Higher ADCs with TOP1i Payloads Achieve Higher Clinical DAR, Allowing for Increased Payload Delivery Doses than ADCs with Microtubule Inhibitor Payloads Clinical Doses of
Slide 16: IM-1021 Preclinical Activity Supports Development in Lymphoma and Solid Tumors
IM-1021 Preclinical Activity Supports Development in Lymphoma and Solid Tumors IM-1021 Achieves Tumor Regressions in Jeko-1 MCL IM-1021 Achieves 8/8 CRs at 2.5 mg/kg in NSCLC Model PDX Model Vehicle 3,000 IM-1021 2.5 mpk qw*3 2500 IM-1021 5 mpk qw*3 Vehicle IM-1021 2.5 mpk qw*3 MK-2140 2.5 mpk qw*3
Slide 17: Clinical Development Plan: Rapid Establishment of PoC
Clinical Development Plan: Rapid Establishment of PoC To Enable Pivotal Studies Across Multiple Indications Part A: Dose Escalation Part B: Indication-Specific Dose Expansion Population includes: Dose escalation design: Population includes: Dose expansion design: • R/R B-cell lymphoma • mTPI-2 adapt
Slide 18: ADC Discovery Strategy
ADC Discovery Strategy 18
Slide 19: Immunome's Experienced Team is Positioned to Develop the Next Generation of ADCs
Immunome’s Experienced Team is Positioned to Develop the Next Generation of Transformative ADCs Exceptional ADC Expertise Research Capabilities • ADC-focused discovery team with deep experience in • Numerous programs in lead optimization or preclinical ADC target selection, design, and optimization
Slide 20: Rigorous Target Validation and Optimized ADC Design Unlocks New ADC Targets
Rigorous Target Validation and Optimized ADC Design Unlocks New ADC Targets Majority of ADC Activity is Concentrated in a Immunome ADC Strategy Small Number of Targets 10 Targets Account for 50% of Active Clinical ADC Programs1 • Targets: Prioritize targets with compelling biology and no approved AD
Slide 21: Proprietary HC74 Payload Designed to be Best-in-Class TOP1i
Proprietary HC74 Payload Designed to be Best-in-Class TOP1i Shown to Overcome Multiple Resistance Mechanisms Design Goal HC74 ADCs DXd ADCs Low efflux potential overcomes High efflux potential leads to Overcome Payload Resistance payload resistance mediated by X primary and acquired payload transpor
Slide 22: HC74 TOP1i Payload and ADCs Shows Superior Properties to DXd
HC74 TOP1i Payload and ADCs Shows Superior Properties to DXd Lower efflux ratio may Increased permeability supports Enhanced stability leads to overcome chemo-resistance superior bystander effect increased payload delivery Payload Efflux1 Payload Permeability2 Payload Loss at Day 7 DXd 79 DXd 2 DXd
Slide 23: Sensitivity to Efflux Meaningfully Limits the Clinical Efficacy of Existing TOP1 ADCs
Sensitivity to Efflux Meaningfully Limits the Clinical Efficacy of Existing TOP1 ADCs High ABCB1 Expression Correlates with Lower ORR High ABCC1 Expression is Associated with Shorter and PFS in HER2+ CRC Patients Treated With T-DXd1 OS in Breast Cancer Patients Treated with T-DXd2 ABCC1 Expression Q
Slide 24: HC74 ADC Shows Activity in a CRC Model Refractory to Other TOP1i Agents
HC74 ADC Shows Activity in a CRC Model Refractory to Other TOP1i Agents HC74 ADCs Overcome Primary Resistance to T-DXd or Irinotecan in ABCB1+ CRC Tumors ABCB1 Expression Post T-DXd Failure Post Irinotecan Failure HCT-15 HCT-15 HCT-15 2000 2000 Tumor Volume (mm3) Tumor Volume (mm3) 1500 1500 HCT-15
Slide 25: HC74 Payload Demonstrates Ability to Overcome Acquired DXd Resistance
Immunome's HC74 Payload Demonstrates Ability to Overcome Acquired DXd Resistance NCI-N87R Tumor Cells Overexpress ABCC1 HC74 Overcomes Acquired DXd Resistance NCI-N87R (DXd-R Gastric) 1200 Vehicle T-DXd(8), 3mg/kg 1000 T-HC74(8), 3mg/kg Tumor Volume (mm3) 800 600 400 200 0 0 7 14 21 28 Days Post Tre
Slide 26: HC74 ADC Demonstrates Superior Bystander Activity vs. DXd ADC
HC74 ADC Demonstrates Superior Bystander Activity vs. DXd ADC Potential for Greater HC74 Efficacy in Target Heterogenous Tumors Clonal Preclinical Models Do Not Capture Expression Heterogeneity HC74 ADC Demonstrates Durable Response in NSCLC Model of Tumor Heterogeneity NCI-H292 Bystander Model (75%
Slide 27: Novel ADC Development Candidates
Novel ADC Development Candidates Three ADCs Against Undisclosed Targets Expressed in Solid Tumors 27
Slide 28: IM-1617 Pursues a Novel ADC Target with Multi-Indication Solid Tumor Potential
IM-1617 Pursues a Novel ADC Target with Multi-Indication Solid Tumor Potential Target Properties IM-1617’s Target is Expressed in Solid Tumor Indications with Significant Unmet Need • Tumor Expression: Major solid tumors including colorectal, NSCLC, breast, and ovarian • Non-Obvious Target: Overlook
Slide 29: IM-1617 is a Potential First-in-Class ADC With Robust Preclinical Activity
IM-1617 is a Potential First-in-Class ADC With Robust Preclinical Activity IM-1617 Design Considerations In Vivo Activity • Antibody selected for Colorectal (HCT116) Esophageal (KYSE30) 3000 Vehicle attributes that drive tumor Isotype ADC, 5 mg/kg 3000 Vehicle Isotype ADC, 5 mg/kg Mean Tumor Volume
Slide 30: IM-1340 is a Potential First-in-Class ADC Against a Novel Solid Tumor Receptor
IM-1340 is a Potential First-in-Class ADC Against a Novel Solid Tumor Receptor Identifying a Unique Expression Profile IM-1340’s Target is Expressed in Neuroendocrine Tumors, Lung, and Prostate • Tumor Expression: Spans neuroendocrine tumors and carcinomas 100 Negative • Tumor Biology: Target known
Slide 31: IM-1340 Shows Robust Efficacy in a Range of Models
IM-1340 Shows Robust Efficacy in a Range of Models IM-1340 Design Considerations In Vivo Activity • High affinity antibody selected to SCLC (NCI-H1105) NSCLC (CALU6) drive efficacy 2000 Vehicle Isotype ADC, 5 mg/kg Vehicle Mean Tumor Volume (mm3) Mean Tumor Volume (mm3) IM-1340, 1 mg/kg 2500 Isotype
Slide 32: IM-1335: ADC Optimization Driven by Understanding Biology of a Known Target
IM-1335: ADC Optimization Driven by Understanding Biology of a Known Target Revisiting a Target with Demonstrated Clinical Efficacy In Vivo Activity • IM-1335 shares a target with an ADC that showed clinical activity but was ultimately discontinued Solid Tumor Indication 2000 Vehicle • Immunome iden
Slide 33: Additional Discovery-Stage Candidates Demonstrate Solid Tumor Activity
Additional Discovery-Stage Candidates Demonstrate Solid Tumor Activity • Immunome has generated in vivo data In Vivo Preclinical Efficacy for Three Additional Candidates for over a dozen distinct targets, with SCLC (NCI-H446) multiple programs currently 3000 Vehicle Mean Tumor Volume (mm3) Isotype A
Slide 34: IM-3050 FAP-Targeted Radioligand Therapy
IM-3050 FAP-Targeted Radioligand Therapy 34
Slide 35: FAP Is a Promising RLT Target with Pan-Cancer Potential
FAP Is a Promising RLT Target with Pan-Cancer Potential Fibroblast Activation Protein (FAP) is a cell surface FAP imaging shows high expression across protease with low expression in normal tissue 15 distinct tumor types • FAP is overexpressed on cancer-associated fibroblasts, the most common tumor
Slide 36: Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened
Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened Immunome has systematically Immunome Approach selected a ligand, linker, albumin Example Structure: Proven structure used by Pluvicto and Lutathera to binding domain, and payload to Optimized linker deliver Lu-177 isot
Slide 37: IM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential
IM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential In vivo data show single dose antitumor activity and tolerability Tumor Regression in U87MG No Weight Loss Observed Potential Best-in-Class Model Characteristics Vehicle Vehicle Sub-nanomolar affinity 1200 120 IM-3050, 150 mCi IM-3050, 15
Slide 38: Building the Foundation of the Next Transformative ADC Company
Building the Foundation of the Next Transformative ADC Company • Fully enrolled Phase 3 trial for varegacestat with topline data expected before the end of 2025 • Clinical and IND-stage programs with best-in-class or first-in-class potential: • IM-1021: ROR1 ADC with objective responses observed at